linguistic:paraphrasing, quality:correction
Chemotherapy

The FOLFIRINOX chemotherapy regimen using four drugs was found more effective than gemcitabine, but with substantial side effects, thus only suitable for people with good performance status. This is also true of protein-bound paclitaxel (nab-paclitaxel), which was licensed by the FDA in 2013 for use with gemcitabine in pancreas cancer. By the end of 2013, either singular FOLFIRINOX or gemcitabine in combination with nab-paclitaxel (Note:) were regarded as good choices for those able to tolerate the side-effects, and singular gemcitabine remained an effective option for those who were not. Regimen changes during this period only increased survival times by a few months.